Business Wire

CA-FORESCOUT

6.12.2023 07:02:34 CET | Business Wire | Press release

Share
Critical Infrastructure Still at High Risk: Forescout Research Spotlights 21 New Vulnerabilities

Forescout, a global cybersecurity leader, today released “SIERRA:21 – Living on the Edge,” an analysis of 21 newly discovered vulnerabilities within OT/IoT routers and open-source software components. The report — produced by Forescout Research – Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in critical infrastructure — emphasizes the continued risk to critical infrastructure and sheds light on possible mitigations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205915662/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sierra:21 Infographic (Source: Forescout)

“SIERRA:21 – Living on the Edge” features research into Sierra Wireless AirLink cellular routers and some of its open-source components, such as TinyXML and OpenNDS. Sierra Wireless routers are popular — an open database of Wi-Fi networks shows 245,000 networks worldwide running Sierra Wireless for a variety of applications. For example, Sierra Wireless routers are used for police vehicles connecting to a central network management system or to stream surveillance video, in manufacturing plants for industrial asset monitoring, in healthcare facilities providing temporary connectivity and to manage electric vehicle charging stations. The 21 new vulnerabilities have the potential to stop vital communications that could impact everyday life.

Read the blog: Forescout Vedere Labs discloses 21 new vulnerabilities affecting OT/IoT routers

Forescout Research further finds:

  • The attack surface is expansive with 86,000 vulnerable routers still exposed online. Less than 10% of these routers are confirmed to be patched against known previous vulnerabilities found since 2019.
  • Regions with the highest number of exposed devices includes:
    • 68,605 devices in The United States
    • 5,580 devices in Canada
    • 3,853 devices in Australia
    • 2,329 devices in France
    • 1,001 devices in Thailand
  • Among the 21 vulnerabilities, one has critical severity (CVSS score 9.6), nine have high severity and 11 have medium severity. These vulnerabilities allow attackers to steal credentials, take control of a router by injecting malicious code, persist on the device and use it as an initial access point into critical networks.
  • Patching can’t fix everything. 90 percent of devices exposing a specific management interface have reached end of life, meaning they cannot be further patched.
  • It’s an uphill battle to secure supply chain components. Open-source software elements continue to go unchecked and increase the attack surface of critical devices, leading to vulnerabilities that may be hard for organizations to track and mitigate.

“We are raising the alarm today because there remain thousands of OT/IoT devices representing an increased attack surface that requires attention,” advises Elisa Constante, VP of Research, Forescout Research – Vedere Labs. “Vulnerabilities impacting critical infrastructure are like an open window for bad actors in every community. State-sponsored actors are developing custom malware to use routers for persistence and espionage. Cybercriminals are also leveraging routers and related infrastructure for residential proxies and to recruit into botnets. Our discoveries reaffirm the need for heightened awareness of the OT/IoT edge devices that are so often neglected.”

Sierra Wireless and OpenDNS have issued patches for the identified vulnerabilities. TinyXML is an abandoned open source project, so the upstream vulnerabilities will not be fixed and must be addressed downstream.

For more information, download the full report, “SIERRA:21 – Living on the Edge,” now at https://www.forescout.com/resources/sierra21-vulnerabilities.

Additional Resources:

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205915662/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye